1701 Stock Overview
Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cenra Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$21.15 |
| 52 Week High | NT$26.40 |
| 52 Week Low | NT$20.20 |
| Beta | 0 |
| 1 Month Change | 3.42% |
| 3 Month Change | -4.94% |
| 1 Year Change | -8.84% |
| 3 Year Change | -9.23% |
| 5 Year Change | 13.40% |
| Change since IPO | -38.58% |
Recent News & Updates
Recent updates
China Chemical & Pharmaceutical's (TWSE:1701) Dividend Will Be Reduced To NT$0.50
Jul 12
Here's Why We Think China Chemical & Pharmaceutical (TPE:1701) Is Well Worth Watching
Apr 25We Think China Chemical & Pharmaceutical (TPE:1701) Can Stay On Top Of Its Debt
Apr 07The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 34% And Shareholders Are Holding On
Mar 17China Chemical & Pharmaceutical Co., Ltd.'s (TPE:1701) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
Feb 24Is China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) A Good Fit For Your Dividend Portfolio?
Jan 27
Does China Chemical & Pharmaceutical (TPE:1701) Have A Healthy Balance Sheet?
Jan 06The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 22% And Shareholders Are Holding On
Dec 16China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Nov 26Shareholder Returns
| 1701 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 0% | 2.8% | 3.2% |
| 1Y | -8.8% | -0.02% | 27.5% |
Return vs Industry: 1701 underperformed the TW Pharmaceuticals industry which returned 14.7% over the past year.
Return vs Market: 1701 underperformed the TW Market which returned 30.6% over the past year.
Price Volatility
| 1701 volatility | |
|---|---|
| 1701 Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 3.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.7% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1701 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1701's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | n/a | Chih-Yung Wu | www.cenra.com |
Cenra Inc. engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals. It offers active pharmaceutical ingredients, generic drugs for human use, over to the counter drugs, health care products for the prevention of diseases and self-care, home care and cosmetics, and animal healthcare products. The company also research and development, contracting manufacturing and international business, sale and distribution of pharmaceutical brands, and senior care services.
Cenra Inc. Fundamentals Summary
| 1701 fundamental statistics | |
|---|---|
| Market cap | NT$6.01b |
| Earnings (TTM) | NT$355.20m |
| Revenue (TTM) | NT$8.87b |
16.2x
P/E Ratio0.6x
P/S RatioIs 1701 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1701 income statement (TTM) | |
|---|---|
| Revenue | NT$8.87b |
| Cost of Revenue | NT$5.61b |
| Gross Profit | NT$3.26b |
| Other Expenses | NT$2.91b |
| Earnings | NT$355.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.38 |
| Gross Margin | 36.79% |
| Net Profit Margin | 4.00% |
| Debt/Equity Ratio | 36.9% |
How did 1701 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/04 10:13 |
| End of Day Share Price | 2024/09/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cenra Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wei Zheng Kit | Citigroup Inc |
| Ryan Liu | IBTS Investment Consulting Co., Ltd. |
| Regina Lee | Jih Sun Securities Investment Consulting Co., Ltd. |